Becton, Dickinson and Company
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Thomas E. Polen Jr.
- Full Time Employees
- 70,000
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 1 Becton Drive Franklin Lakes NJ United States of America 07417-1880
- IPO Date
- Feb 21, 1973
- CIK
- 0000010795
- Website
- bd.com
- Similar Companies
- Business
- Becton, Dickinson and Company (BDX) manufactures and distributes medical devices, instrument systems, and reagents worldwide. The company develops, produces, and sells a broad portfolio of products including syringes, catheters, infusion therapy devices, and diagnostic systems; safety-engineered sharps and vascular access products; BD Alaris infusion pumps and Pyxis medication management solutions; BD FACSAria flow cytometers and Rhapsody single-cell analysis platforms; and laboratory automation systems such as BD Kiestra and BD Synapsys informatics. BD operates in three main segments—BD Medical, BD Life Sciences, and BD Interventional—serving healthcare facilities, laboratories, pharmaceutical companies, and research institutions across North America, Europe, Asia-Pacific, and emerging markets. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD maintains a global presence with manufacturing facilities in more than 50 countries. In recent developments, BD completed the spin-off of its Biosciences solution business into a standalone entity in early 2025, enabling focused growth in high-margin diagnostics and cell analysis; the company also expanded its partnership with GE HealthCare for integrated medication management technologies and launched new Alaris iPC infusion pump features to enhance cybersecurity and interoperability.
BD to Announce Financial Results for its Third Quarter of Fiscal 2026
Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?
Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom
5 Dividend Kings Long-Term Investors Should Own for the Next 20 Years
Becton, Dickinson - Stable Undervaluation In 1Q26, Upside Is There
BD Awarded Vizient Innovative Technology Contract for CentroVena One™ Insertion System
5 Dividend Stocks to Buy and Hold Forever
3 Excellent Dividend Stocks to Buy on the Dip
Rep Thomas Kean just filed 4 new congressional stock trades
The Healthcare M&A Wave
Here's Why You Should Retain BDX Stock in Your Portfolio Now
Dividend Champion, Contender, And Challenger Highlights: Week Of June 7
Jim Cramer: Buy Becton Dickinson, This Tech Stock Has Too High Valuation
Best 3 Blue Chip Stocks to Buy After a Market Pullback -- Including Microsoft (MSFT) Stock
BD Launches Elyra Thulium Fiber Laser System for Kidney Stone Care
BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System
Peter Menziuso Named EVP and President, BD Interventional
AI, Robotics Key to Transforming Health Care: BD CEO
Becton, Dickinson and Company (BDX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Is Becton Dickinson & Co (BDX) a Bargain After 4.2% Drop? GF Value Says Undervalued